(Q51900617)

17 April 2018

title

No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. (English)

1 reference

17 April 2018

0 references

1 reference

Raquel E Gur

1 reference

17 April 2018

Ruben C Gur

1 reference

17 April 2018

Warren B Bilker

object named as

Warren Bilker

1 reference

17 April 2018

author name string

Christian G Kohler

1 reference

17 April 2018

Elizabeth A Martin

1 reference

17 April 2018

Evan Kujawski

1 reference

17 April 2018

publication date

1 September 2007

1 reference

17 April 2018

Cognitive Neuropsychiatry

published in

1 reference

17 April 2018

volume

1 reference

17 April 2018

issue

1 reference

17 April 2018

page(s)

412-421

1 reference

17 April 2018

The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms

cites work

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Effect of antipsychotic medication on speed of information processing in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Facial affect and affective prosody recognition in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Efficacy and tolerability of low-dose donepezil in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Guanfacine treatment of cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Cholinergic enhancement improves performance on working memory by modulating the functional activity in distinct brain regions: a positron emission tomography regional cerebral blood flow study in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Computerized neurocognitive scanning: II. The profile of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

21 January 2018

Acetylcholine and memory

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Effects of antipsychotic treatment on emotion perception deficits in first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Donepezil for memory dysfunction in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Emotion recognition deficit in schizophrenia: association with symptomatology and cognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Facial emotion recognition in schizophrenia: intensity effects and error pattern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Neurocognitive impairment across the lifespan in schizophrenia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Donepezil in schizophrenia--is it helpful? An experimental design case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

5-HT6 receptors: a novel target for cognitive enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Management of the negative symptoms of schizophrenia: new treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Neuropsychological function in schizophrenia. Selective impairment in memory and learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Perception of happy and sad facial expressions in chronic schizophrenia: evidence for two evaluative systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

A rating scale for mania: reliability, validity and sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13546800701307263

10.1080/13546800701307263

21 January 2018

Identifiers

DOI

1 reference

17 April 2018

1 reference

17 April 2018